JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Istradefylline (formerly KW6002; KW 6002; KW-6002; Nourianz), a caffeine derivative, is an orally bioavailable and selective adenosine A2A receptor (A2AR) antagonist with anti-PD (Parkinson's disease) effects. It inhibits A2A receptor (A2AR) with a Ki of 2.2 nM. It has been approved to be used as an add-on treatment to levodopa/carbidopa for patients with Parkinson's disease experiencing 'off' episodes. Istradefylline reduces 'off' periods resulting from long-term treatment with the antiparkinson drug levodopa.
References: J Neurosci. 2001 May 15; 21(10):RC143; Psychopharmacology (Berl). 1999 Nov; 147(1):90-5.
Related CAS: 160434-48-0 (4-Desmethyl Istradefylline)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!